€ 67.5
Key Takeaways
Risk factor
Negligible price volatility
Profitability factor
Very strong margins and returns
About
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair valu
Target Price
The average target price of ORNBV.HE is 68 and suggests 0% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
